Jonathan Licht - Publications

Cancer Center Icahn School of Medicine at Mount Sinai, New York, NY, United States 

153 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Therapy. PMID 35332245 DOI: 10.1038/s41417-022-00452-7  0.328
2021 Li J, Hlavka-Zhang J, Shrimp JH, Piper C, Dupere-Richer D, Roth JS, Jing D, Casellas Roman HL, Troche C, Swaroop A, Kulis M, Oyer JA, Will CM, Shen M, Riva A, ... ... Licht JD, et al. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia. Cancer Discovery. PMID 34417224 DOI: 10.1158/2159-8290.CD-20-1771  0.315
2021 Zee BM, Poels KE, Yao CH, Kawabata KC, Wu G, Duy C, Jacobus WD, Senior E, Endress JE, Jambhekar A, Lovitch SB, Ma J, Dhall A, Harris IS, Blanco MA, ... ... Licht JD, et al. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. Iscience. 24: 102651. PMID 34151238 DOI: 10.1016/j.isci.2021.102651  0.51
2021 Licht JD, Bennett RL. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clinical Epigenetics. 13: 115. PMID 34001289 DOI: 10.1186/s13148-021-01100-x  0.301
2021 De Matos Simoes R, Barwick BG, Shirasaki R, Dashevsky O, Gandolfi S, Tang H, Glassner B, Groen RW, Auclair D, Culhane A, Tsherniak A, Vazquez F, Licht JD, Boise LH, Mitsiades CS. Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma Blood. 138: 1589-1589. DOI: 10.1182/blood-2021-154359  0.309
2021 Kaestner CL, Sobh A, Li J, Riva A, Bennett RL, Licht JD. Functional CRISPR Screening Identifies Ptprg As a Driver of Migration and Adhesion in NSD2-E1099K ALL Blood. 138: 1149-1149. DOI: 10.1182/blood-2021-154009  0.316
2021 Sobh A, Kaestner CL, Li J, Riva A, Bennett RL, Licht JD. Adenylate Kinase 2 Is a Selective Multiple Myeloma Cell Dependency That Is Preferentially Essential in NSD2-Overexpressing Cells Blood. 138: 1586-1586. DOI: 10.1182/blood-2021-153284  0.319
2021 Li J, Lhoumaud P, Riva A, Piper C, Dupere-Richer D, Casellas Roman H, Sobh A, Kaestner CL, Swaroop A, Kulis M, Bennett RL, Skok J, Licht JD. Dysregulation of Epigenetic Landscape Uncovered the Mechanisms Underlying the Relapse of Pediatric Acute Lymphoblastic Leukemia with NSD2 Mutation Blood. 138: 3297-3297. DOI: 10.1182/blood-2021-149985  0.417
2020 Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J, Phillip JM, Elemento O, Scott DW, Béguelin W, Licht JD, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. PMID 33299181 DOI: 10.1038/s41586-020-3017-y  0.472
2020 Ordonez R, Kulis M, Russinol N, Chapaprieta V, Carrasco-Leon A, Garcia-Torre B, Charampopoulou S, Clot G, Beekman R, Meydan C, Duran-Ferrer M, Verdaguer-Dot N, Vilarrasa-Blasi R, Soler-Vila P, Garate L, ... ... Licht JD, et al. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research. PMID 32820006 DOI: 10.1101/Gr.265520.120  0.505
2020 De Matos Simoes R, Shirasaki R, Tang H, Yamano S, Barwick BG, Gandolfi S, Dhimolea E, Downey-Kopyscinski SL, Dashevsky O, Glassner B, Sheffer M, Kansara D, Bariteau M, Sorrell J, Gupta V, ... ... Licht JD, et al. POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma Blood. 136: 18-19. DOI: 10.1182/blood-2020-142580  0.326
2020 Li J, Piper C, Dupere-Richer D, Casellas Roman H, Swaroop A, Troche C, Oyer J, Will C, Riva A, Bennett RL, Licht JD. NSD2-E1099K Mutation Leads to Glucocorticoid-Resistant B Cell Lymphocytic Leukemia in Mice Blood. 136: 3-4. DOI: 10.1182/blood-2020-141295  0.34
2020 Dupere-Richer D, Maji S, Riva A, Quickstad G, Kulis M, Monagle D, Martín-Subero JI, Bennett RL, Licht JD. KDM6A Controls Genes Modulating Immune Surveillance in Multiple Myeloma Blood. 136: 14-14. DOI: 10.1182/BLOOD-2020-141285  0.39
2020 Sobh A, Kaestner C, Li J, Riva A, Bennett RL, Licht JD. Adenylate Kinase 2 Is a Selective Dependency in NSD2-High Multiple Myeloma Blood. 136: 31-31. DOI: 10.1182/blood-2020-141266  0.318
2019 Bennett RL, Bele A, Small EC, Will CM, Nabet B, Oyer JA, Huang X, Ghosh RP, Grzybowski AT, Yu T, Zhang Q, Riva A, Lele TP, Schatz GC, Kelleher NL, ... ... Licht JD, et al. A Mutation in Histone H2B Represents a New Class of Oncogenic Driver. Cancer Discovery. PMID 31337617 DOI: 10.1158/2159-8290.Cd-19-0393  0.346
2019 Huang X, LeDuc RD, Fornelli L, Schunter AJ, Bennett RL, Kelleher NL, Licht JD. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding. The Journal of Biological Chemistry. PMID 31248990 DOI: 10.1074/Jbc.Ra118.006159  0.36
2019 Recker KL, Norton S, Sobh A, Riva A, Chang K, Kuznetsov J, Durante M, Flores F, Bennett RL, Vakoc C, Smalley K, Harbour W, Licht JD. Synthetic Lethal Screen to Identify Molecular Mechanisms that Drive Uveal Melanoma Uf Journal of Undergraduate Research. 21. DOI: 10.32473/ufjur.v21i1.108370  0.309
2019 Li J, Troche C, Zhang JH, Shrimp J, Roth JS, Jing D, Swaroop A, Kulis M, Oyer J, Will C, Dupere-Richer D, Riva A, Pipe C, Sobn A, Norton S, ... ... Licht JD, et al. A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL Blood. 134: 3758-3758. DOI: 10.1182/blood-2019-126910  0.382
2019 Sobh A, Kaestner C, Riva A, Licht JD. Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma Blood. 134: 3757-3757. DOI: 10.1182/blood-2019-125951  0.362
2019 Emmons M, Flores F, Koomen J, Seto E, Messina J, Lau E, Licht J, Smalley K. Abstract 3800: HDAC8 regulates plasticity and escape from therapy in BRAF mutant melanoma Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3800  0.316
2019 Faiao-Flores F, Emmons M, Durante M, Saha B, Fang B, Koomen J, Chellappan S, Maria-Engler S, Licht J, Harbour W, Smalley K. Abstract 378: HDAC inhibition enhances MEK antagonist therapy in uveal melanoma through combined blockade of YAP, AKT and RTK signaling Cancer Research. 79: 378-378. DOI: 10.1158/1538-7445.Sabcs18-378  0.333
2019 Ordoñez R, Kulis M, Russiñol N, Chapaprieta V, Beekman R, Meydan C, Duran-Ferrer M, Verdaguer-Dot N, Clot G, Vilarrasa-Blasi R, Garate L, Miranda E, Carrasco A, Ezponda T, Martens JH, ... ... Licht JD, et al. CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA Hemasphere. 3: 236. DOI: 10.1097/01.HS9.0000560560.72691.D3  0.41
2019 de Matos Simoes R, Shirasaki R, Tang H, Sheffer M, Dashevsky O, Downey-Kopyscinski S, Dhimolea E, Bariteau M, Licht J, Glassner BJ, Levy J, Auclair D, Vazquez F, Tsherniak A, Hahn W, et al. CRISPR-based functional genomics landscape of genes recurrently mutated in MM Clinical Lymphoma Myeloma and Leukemia. 19: e77-e78. DOI: 10.1016/J.Clml.2019.09.123  0.314
2019 Shirasaki R, de Matos Simoes R, Downey-Kopyscinski S, Matthews G, Hu Y, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Hengeveld P, Dempster J, Meyers R, Bryan J, Dharia N, McFarland J, ... ... Licht J, et al. CRISPR studies identify genes preferentially essential for myeloma cells vs. other neoplasias: implications for future therapies selective against MM Clinical Lymphoma Myeloma and Leukemia. 19: e48-e49. DOI: 10.1016/J.Clml.2019.09.073  0.359
2018 Alzrigat M, Jernberg-Wiklund H, Licht JD. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity. Epigenomes. 2. PMID 30761216 DOI: 10.3390/epigenomes2030016  0.35
2018 Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, Licht JD, Zhao JC, Yu J. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Reports. 25: 2808-2820.e4. PMID 30517868 DOI: 10.1016/J.Celrep.2018.11.035  0.307
2018 Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, Bulic M, Durham BH, Wen QJ, Crispino JD, MacKerell AD, Bennett RL, Kelleher NL, Licht JD. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene. PMID 30171259 DOI: 10.1038/S41388-018-0474-Y  0.37
2018 Licht JD. DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A. Transactions of the American Clinical and Climatological Association. 129: 24-36. PMID 30166694  0.377
2018 Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism. Blood. PMID 29844011 DOI: 10.1182/Blood-2017-10-811760  0.344
2018 Luo H, Wang F, Zha J, Li H, Yan B, Du Q, Yang F, Sobh A, Vulpe C, Drusbosky L, Cogle C, Chepelev I, Xu B, Nimer SD, Licht J, et al. CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. Blood. PMID 29760161 DOI: 10.1182/Blood-2017-11-814319  0.476
2018 Li J, Troche C, Swaroop A, Kulis M, Oyer J, Will C, Dupere-Richer D, Riva A, Pipe C, Norton S, Bennett RL, Licht JD. A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance of Acute Lymphoblastic Leukemia Blood. 132: 653-653. DOI: 10.1182/BLOOD-2018-99-116309  0.377
2018 Rahmat M, Haradhvala N, Sklavenitis-Pistofidis R, Park J, Huynh D, Bustoros M, Berrios B, Reidy M, Perilla-Glen A, Rivotto B, Hornburg K, Dorfman DM, Licht JD, Getz G, Ghobrial IM. Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression Blood. 132: 3896-3896. DOI: 10.1182/BLOOD-2018-99-115046  0.376
2018 Dupere-Richer D, Li J, Maji S, Pipe C, Norton S, Ezponda T, Bennett RL, Licht JD. Loss of KDM6A/UTX Accelerate the Development of Multiple Myeloma Blood. 132: 1004-1004. DOI: 10.1182/BLOOD-2018-99-113835  0.36
2018 Licht JD. Epigenetic Regulation and Therapeutic Targeting in Myeloma Blood. 132: SCI-37-SCI-37. DOI: 10.1182/BLOOD-2018-99-109522  0.42
2018 Venugopal K, Dupéré-Richer D, Licht J, Guryanova O. Abstract 343: Targeting DNA replication as a therapeutic strategy for acute myeloid leukemia with DNMT3A mutations Cancer Research. 78: 343-343. DOI: 10.1158/1538-7445.Am2018-343  0.424
2017 Ezponda T, Dupéré-Richer D, Will CM, Small EC, Varghese N, Patel T, Nabet B, Popovic R, Oyer J, Bulic M, Zheng Y, Huang X, Shah MY, Maji S, Riva A, ... ... Licht JD, et al. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition. Cell Reports. 21: 628-640. PMID 29045832 DOI: 10.1016/J.Celrep.2017.09.078  0.371
2017 Dupere-Richer D, Ezponda T, Will C, Small EC, Varghese N, Tej P, Huang X, Yupeng Z, Tonon G, Kelleher N, Keats J, Licht JD. Abstract 12: KMD6A/UTX loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition Epigenetics. 23: 12-12. DOI: 10.1158/1557-3265.Hemmal17-12  0.402
2016 Schauwecker SM, Kim JJ, Licht JD, Clevenger CV. Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-Induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells. The Journal of Biological Chemistry. PMID 28035005 DOI: 10.1074/Jbc.M116.764233  0.322
2016 Béguelin W, Teater M, Gearhart MD, Calvo Fernández MT, Goldstein RL, Cárdenas MG, Hatzi K, Rosen M, Shen H, Corcoran CM, Hamline MY, Gascoyne RD, Levine RL, Abdel-Wahab O, Licht JD, et al. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell. 30: 197-213. PMID 27505670 DOI: 10.1016/J.Ccell.2016.07.006  0.528
2016 Nichol JN, Dupéré-Richer D, Ezponda T, Licht JD, Miller WH. H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer. Advances in Cancer Research. 131: 59-95. PMID 27451124 DOI: 10.1016/Bs.Acr.2016.05.001  0.357
2015 McConnell MJ, Durand L, Langley E, Coste-Sarguet L, Zelent A, Chomienne C, Kouzarides T, Licht JD, Guidez F. Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases. Epigenetics & Chromatin. 8: 38. PMID 26405459 DOI: 10.1186/S13072-015-0030-8  0.391
2015 Nabet B, Ó Broin P, Reyes JM, Shieh K, Lin CY, Will CM, Popovic R, Ezponda T, Bradner JE, Golden AA, Licht JD. Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. Cell Reports. 12: 1300-13. PMID 26279576 DOI: 10.1016/J.Celrep.2015.06.078  0.303
2015 Saloura V, Cho HS, Kiyotani K, Alachkar H, Zuo Z, Nakakido M, Tsunoda T, Seiwert T, Lingen M, Licht J, Nakamura Y, Hamamoto R. WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck. Molecular Cancer Research : McR. 13: 293-304. PMID 25280969 DOI: 10.1158/1541-7786.Mcr-14-0292-T  0.433
2015 Oyer J, Will C, Huang X, Ezponda T, Popovic R, Zheng Y, Kelleher NL, Licht JD. Allele-Specific Crispr Targeting Reveals Epigenetic and Phenotypic Effects of a MMSET Gain of Function Mutation Found in Relapsed Acute Lymphoblastic Leukemia Blood. 126: 437-437. DOI: 10.1182/Blood.V126.23.437.437  0.358
2015 Ezponda T, Popovic R, Zheng Y, Nabet B, Will C, Small E, Occhionorelli M, Tonon G, Keats J, Kelleher N, Licht JD. Abstract B32: Loss of the histone demethylase UTX alters the gene expression prolife and contributes to the malignant phenotype of multiple myeloma cells. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B32  0.417
2015 Bainer R, Yui Y, Mumenthaler S, Mallick P, Liu L, Wu H, Podlaha O, Michor F, Liphardt J, Licht J, Weaver V. Abstract PR09: Extracellular stiffness cues drive spatial reorganization of the genome to globally constrain RNA abundance Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-Pr09  0.348
2015 Nabet B, Broin PO, Reyes J, Shieh K, Lin CY, Will CM, Popovic R, Ezponda T, Bradner JE, Golden AA, Licht JD. Abstract 2209: Deregulation of the Ras-Erk signaling axis modulates the enhancer landscape Cancer Research. 75: 2209-2209. DOI: 10.1158/1538-7445.Am2015-2209  0.32
2014 Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, ... ... Licht JD, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Reports. 9: 1841-55. PMID 25482556 DOI: 10.1016/J.Celrep.2014.11.004  0.466
2014 Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small EC, Hua Y, Bulic M, Jiang Y, Carrara M, Calogero RA, ... ... Licht JD, et al. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. Plos Genetics. 10: e1004566. PMID 25188243 DOI: 10.1371/Journal.Pgen.1004566  0.355
2014 Ezponda T, Licht JD. Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5001-8. PMID 24987060 DOI: 10.1158/1078-0432.CCR-13-2499  0.341
2014 Small EC, Xi L, Wang JP, Widom J, Licht JD. Single-cell nucleosome mapping reveals the molecular basis of gene expression heterogeneity. Proceedings of the National Academy of Sciences of the United States of America. 111: E2462-71. PMID 24889621 DOI: 10.1073/Pnas.1400517111  0.361
2014 Yoon JH, Kim MY, Koh DI, Licht JD, Kim K, Hur MW. Promyelocytic leukemia zinc finger-retinoic acid receptor - (PLZF-RAR-), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes Won-Il Choi Journal of Biological Chemistry. 289: 18641-18656. PMID 24821728 DOI: 10.1074/jbc.M113.538777  0.379
2014 Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, Carpenter Z, Allegretta M, Okot-Kotber CI, Patel JP, Melnick A, Levine RL, Ferrando A, Mackerell AD, Kelleher NL, Licht JD, et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 28: 198-201. PMID 23823660 DOI: 10.1038/Leu.2013.204  0.445
2014 Ezponda T, Popovic R, Zheng Y, Nabet B, Will C, Small EC, Occhionorelli M, Tonon G, Keats JJ, Kelleher NL, Licht JD. Loss of the Histone Demethylase UTX Contributes to Multiple Myeloma and Sensitizes Cells to EZH2 Inhibitors Blood. 124: 611-611. DOI: 10.1182/Blood.V124.21.611.611  0.384
2014 Beguelin W, Teater M, Popovic R, Jiang Y, Cerchietti L, Shaknovich R, Gascoyne R, Levine R, Abdel-Wahab O, Licht J, Elemento O, Melnick AM. Abstract SY09-03: How deregulation of histone methyltransferases drive malignant transformation of B-cells Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Sy09-03  0.586
2014 Dupéré-Richer D, Kinal M, Pettersson F, Hassawi M, ShaoNing Y, Nielsen TH, Klein K, Ezponda-Itoiz T, Licht JD, Johnson N, Assouline SE, Cerchietti L, Miller WH, Mann KK. Abstract 5538: Development of HDACi resistance in DLBCL leads to a switch in subtype towards a more differentiated B-cell and is associated with increased sensitivity to proteasome inhibition Cancer Research. 74: 5538-5538. DOI: 10.1158/1538-7445.Am2014-5538  0.32
2014 Bainer R, Yui Y, Mumenthaler S, Mallick P, Podlaha O, Michor F, Liphardt J, Licht J, Weaver V. Abstract 2344: 3D extracellular stiffness cues drive localized changes in gene expression Cancer Research. 74: 2344-2344. DOI: 10.1158/1538-7445.Am2014-2344  0.444
2013 Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, ... ... Licht JD, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 23: 677-92. PMID 23680150 DOI: 10.1016/J.Ccr.2013.04.011  0.525
2013 Popovic R, Shah MY, Licht JD. Epigenetic therapy of hematological malignancies: where are we now? Therapeutic Advances in Hematology. 4: 81-91. PMID 23610616 DOI: 10.1177/2040620712466864  0.31
2013 Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, Will C, Neri A, Kelleher NL, Yu J, Licht JD. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene. 32: 2882-90. PMID 22797064 DOI: 10.1038/Onc.2012.297  0.317
2013 Popovic R, Martinez-Garcia E, Zhang Q, Ezponda T, Shah MY, Zhang Y, Jiang Y, Will CM, Small EC, Bulic M, Elemento O, Kelleher N, Kath W, Wang J, Licht JD. MMSET dysregulates gene expression in myeloma through global and focal changes in H3K36 and H3K27 methylation Epigenetics & Chromatin. 6. DOI: 10.1186/1756-8935-6-S1-P66  0.398
2013 Small EC, Zhang Q, Popovic R, Hua Y, Wang J, Licht JD. Genome-wide nucleosome mapping in multiple myeloma Epigenetics & Chromatin. 6. DOI: 10.1186/1756-8935-6-S1-P124  0.384
2013 Teater MR, Hatzi K, Popovich R, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Chung YR, Shaknovich R, Creasy C, Gascoyne RD, Cerchietti L, Levine RL, Abdel-Wahab O, ... Licht JD, et al. EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains Blood. 122: 1-1. DOI: 10.1182/Blood.V122.21.1.1  0.574
2013 Nabet B, Braun R, Popovic R, Licht JD. Abstract 740: Investigating the role of epigenetic mechanisms upon aberrant signaling network activation. Cancer Research. 73: 740-740. DOI: 10.1158/1538-7445.Am2013-740  0.329
2013 Will C, Scholle M, Pierre RS, Shim JH, Cheng ZJ, Popovic R, Patel DJ, Bradner JE, MacKerell AD, Mrksich M, Licht JD. Abstract 1127: MMSET: Can we flip the switch. Cancer Research. 73: 1127-1127. DOI: 10.1158/1538-7445.Am2013-1127  0.338
2012 Licht JD. Aberrant Histone Methylation in Myeloma: What Are the Rules? Blood. 120: SCI-5-SCI-5. DOI: 10.1182/BLOOD.V120.21.SCI-5.SCI-5  0.391
2012 Popovic R, Martinez E, Zhang Q, Ezponda T, Jiang Y, Shah MY, Will C, Small EC, Elemento O, Wang J, Licht JD. MMSET Dysregulates Gene Expression in Myeloma Through Global and Focal Changes in H3K36 and H3K27 Methylation Blood. 120: 523-523. DOI: 10.1182/Blood.V120.21.523.523  0.406
2012 Ezponda-Itoiz T, Popovic R, Shah MY, Martinez-Garcia E, Min D, Will C, Licht JD. Abstract 1046: The histone methyl transferase MMSET/WHSC1 promotes an epithelial-mesenchymal transition and invasive properties of prostate cancer Cancer Research. 72: 1046-1046. DOI: 10.1158/1538-7445.Am2012-1046  0.319
2011 Pettersson F, Miller WH, Nervi C, Gronemeyer HJ, Licht J, Tallman MS, Waxman S. The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells. Cell Death and Differentiation. 18: 1231-3. PMID 21212795 DOI: 10.1038/Cdd.2010.173  0.324
2011 Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 117: 211-20. PMID 20974671 DOI: 10.1182/Blood-2010-07-298349  0.357
2011 Kim MK, Min DJ, Rabin M, Licht JD. Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants. Oncogene. 30: 832-42. PMID 20956941 DOI: 10.1038/onc.2010.452  0.313
2011 Popovic R, Martinez-Garcia E, Sweet SM, Zheng Y, Kelleher NL, Licht JD. MMSET Contributes to Multiple Myeloma Oncogenesis Through Induction of Global Epigenetic Changes and Alteration of the DNA Damage Response, Blood. 118: 3475-3475. DOI: 10.1182/Blood.V118.21.3475.3475  0.376
2011 Petruccelli LA, Rice KL, Pettersson F, Nichol JN, Skoulikas S, Licht JD, Miller WH. Abstract 2136: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors Cancer Research. 71: 2136-2136. DOI: 10.1158/1538-7445.Am2011-2136  0.336
2011 Licht JD, Popovic R, Min D, Martinez-Garcia E, Mrksch M, Kelleher N, Will C, Ezponda T. Abstract PL05-02: MMSET: A pathogenic factor and therapeutic target in multiple myeloma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-Pl05-02  0.4
2010 Min DJ, Licht JD. Partners in crime: Genes within an amplicon collude to globally deregulate chromatin in lymphoma. Cancer Cell. 18: 539-41. PMID 21156276 DOI: 10.1016/j.ccr.2010.11.032  0.323
2010 Lagha M, Sato T, Regnault B, Cumano A, Zuniga A, Licht J, Relaix F, Buckingham M. Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo. Bmc Genomics. 11: 696. PMID 21143873 DOI: 10.1186/1471-2164-11-696  0.457
2010 Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, ... ... Licht JD, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 18: 553-67. PMID 21130701 DOI: 10.1016/J.Ccr.2010.11.015  0.478
2009 Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, Mills KI, Leiva M, Ablain J, Ambardekar C, McConnell MJ, Dick JE, Licht JD. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood. 114: 5499-511. PMID 19855079 DOI: 10.1182/blood-2009-03-206524  0.373
2009 Doulatov S, Notta F, Rice KL, Howell L, Zelent A, Licht JD, Dick JE. PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes & Development. 23: 2076-87. PMID 19723763 DOI: 10.1101/gad.1788109  0.306
2009 Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD, Gore SD, Melnick A. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 114: 3448-58. PMID 19652201 DOI: 10.1182/Blood-2009-01-200519  0.497
2009 Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 114: 2764-73. PMID 19546476 DOI: 10.1182/Blood-2009-02-203547  0.375
2009 Martinez-Garcia E, Popovic R, Min D, Will C, Meyer J, Staudt LM, Lamy L, Lauring J, Cheng Z, Patel D, Licht JD. The MMSET Histone Methyl Transferase Alters Chromatin Structure and Gene Expression in t(4;14) Multiple Myeloma Cells. Blood. 114: 675-675. DOI: 10.1182/Blood.V114.22.675.675  0.418
2009 Petruccelli LA, Pettersson F, Dupere‐Richer D, Rice KL, Licht JD, Miller WH. Abstract A189: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A189  0.374
2008 Petrie K, Guidez F, Zhu J, Howell L, Owen G, Chew YP, Parks S, Waxman S, Licht J, Mittnacht S, Zelent A. Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters. Oncogene. 27: 5260-6. PMID 18504436 DOI: 10.1038/Onc.2008.159  0.492
2008 Polo JM, Ci W, Licht JD, Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells Blood. 112: 644-651. PMID 18487509 DOI: 10.1182/Blood-2008-01-131813  0.503
2008 Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, Sirulnik A, Martinez-Martinez Y, Chesi M, Bergsagel PL, Zhou MM, Waxman S, Leibovitch BA, Walsh MJ, Licht JD. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood. 111: 3145-54. PMID 18156491 DOI: 10.1182/blood-2007-06-092122  0.397
2008 Rice KL, Hormaeche I, McConnell MJ, Doulatov S, Flatow J, Grimwade D, Mills KI, Dick JE, Licht JD. Comprehensive Genomic Screens Reveal Multiple Modes of Action of the PLZF-RAR-α Oncoprotein Blood. 112: 686-686. DOI: 10.1182/BLOOD.V112.11.686.686  0.412
2008 Min D, Meyer J, Martinez-Garcia E, Lauring J, Licht JD. Genome-Wide Chromatin Immunopreciptiation and Gene Expression Analysis Indicates That MMSET Is a Transcriptional Repressor in Vivo Blood. 112: 627-627. DOI: 10.1182/BLOOD.V112.11.627.627  0.379
2008 Zhang W, Ebert BL, Berkofsky-Fessler W, Buzzai M, Sun Y, Xi C, Levine RL, Gilliland DG, Licht JD. Integrative Analysis of Genomic Aberration and Gene Expression Suggests That MPD with Loss of Heterozygosity or Gain of Chromosome 9 Represents a Distinct Entity Blood. 112: 3735-3735. DOI: 10.1182/blood.v112.11.3735.3735  0.303
2008 Lin X, Buzzai M, Levine RL, Berkofsky-Fessler W, Zhang W, Ebert BL, Gilliland DG, Licht JD. NFIB: A Gene Consistently Upregulated in MPD and Frequently Co-Amplified with JAK2V617F Augments Growth of Erythropoietin Dependent Cells Blood. 112: 3727-3727. DOI: 10.1182/blood.v112.11.3727.3727  0.355
2008 Hormaeche I, Rice KL, Zelent A, McConnell MJ, Licht JD. PLZF-RARα Utilizes the Histone Methyl Transferase G9a/GLP and the Histone Demethylase LSD1 to Repress RARα Target Genes and Block Myeloid Differentiation Blood. 112: 198-198. DOI: 10.1182/BLOOD.V112.11.198.198  0.403
2007 Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene. 26: 6697-714. PMID 17934479 DOI: 10.1038/sj.onc.1210755  0.338
2007 Hormaeche I, Licht JD. Chromatin modulation by oncogenic transcription factors: new complexity, new therapeutic targets. Cancer Cell. 11: 475-8. PMID 17560329 DOI: 10.1016/j.ccr.2007.05.005  0.367
2007 Rice KL, Licht JD. HOX deregulation in acute myeloid leukemia. The Journal of Clinical Investigation. 117: 865-8. PMID 17404613 DOI: 10.1172/JCI31861  0.339
2007 Figueroa ME, Fandy T, McConnell MJ, Berkofsky-Fessler W, Nasrallah C, Carraway H, Licht J, Gore SD, Melnick AM. Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells. Blood. 110: 345-345. DOI: 10.1182/Blood.V110.11.345.345  0.572
2007 Licht JD, Rice KL, Hormaeche I, Meyer J, Mills KI, Grimwade D. A Comprehensive Genomic Approach Using Gain of Function Cell Models, Patient Specimens and ChIP-on-CHIP Technologies Identifies PLZF-RARα Target Genes with Potential Roles in t(11;17) Associated APL. Blood. 110: 3168-3168. DOI: 10.1182/blood.v110.11.3168.3168  0.397
2007 Petrie KR, Guidez F, Zhu J, Owen G, Chew YP, Waxman S, Licht JD, Mittnacht S, Arthur Z. Retinoblastoma Protein and the Leukemia-Associated PLZF Transcription Factor Interact To Repress Target Gene Promoters. Blood. 110: 1240-1240. DOI: 10.1182/BLOOD.V110.11.1240.1240  0.406
2006 Hormaeche I, Rice K, Marango J, Guidez F, Zelent A, Licht JD. Physical and Functional Association of PLZF with Histone Methyl Transferase and Histone Demethylase. Blood. 108: 731-731. DOI: 10.1182/BLOOD.V108.11.731.731  0.379
2006 Marango J, Leibovitch BA, Shimoyama M, Nishio H, Waxman S, Walsh MJ, Licht JD. The MMSET Protein Is Tightly Associated with Chromatin, Mediates Methylation of Specific Histone Residues and Forms a Complex with a Histone Demethylase. Blood. 108: 730-730. DOI: 10.1182/blood.v108.11.730.730  0.386
2006 Berkofsky-Fessler W, McConnell M, Neuberg DS, Licht JD. Engineered Expression of JAK2V617F Drastically Changes the Response of Progenitor Cells to Erythropoietin and Partially Mimics the Polycythemia Expression Signature. Blood. 108: 3597-3597. DOI: 10.1182/BLOOD.V108.11.3597.3597  0.334
2006 Rice KL, Melnick A, Ye K, Berkofsky-Fessler W, Licht JD. A Comprehensive Genomic Approach Using Gain of Function and Loss of Function Cell Models and ChIP-on-Chip Technology Identifies Novel Promyelocytic Zinc Finger Protein Target Genes. Blood. 108: 1407-1407. DOI: 10.1182/Blood.V108.11.1407.1407  0.549
2005 Licht JD, Sternberg DW. The molecular pathology of acute myeloid leukemia. Hematology. American Society of Hematology. Education Program. 137-42. PMID 16304371 DOI: 10.1182/asheducation-2005.1.137  0.302
2005 Morrison DJ, English MA, Licht JD. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak Cancer Research. 65: 8174-8182. PMID 16166292 DOI: 10.1158/0008-5472.CAN-04-3657  0.306
2005 Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S, Hormaeche I, McConnell MJ, Pierce S, Cole PA, Licht J, Zelent A. Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Molecular and Cellular Biology. 25: 5552-66. PMID 15964811 DOI: 10.1128/Mcb.25.13.5552-5566.2005  0.462
2005 Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3957-70. PMID 15867201 DOI: 10.1200/JCO.2005.14.498  0.541
2005 Lin W, Jing N, Basson MA, Dierich A, Licht J, Ang SL. Synergistic activity of Sef and Sprouty proteins in regulating the expression of Gbx2 in the mid-hindbrain region. Genesis (New York, N.Y. : 2000). 41: 110-5. PMID 15729686 DOI: 10.1002/Gene.20103  0.379
2005 Guo G, Morrison DJ, Licht JD, Quaggin SE. WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. Journal of the American Society of Nephrology : Jasn. 15: 2851-6. PMID 15504938 DOI: 10.1097/01.ASN.0000143474.91362.C4  0.337
2005 Marango J, Shimoyama M, Leibovitch BA, Zhou MM, Martinez Y, Sirulnik A, Chesi M, Bergsagel PL, Licht JD. The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor. Blood. 106: 358-358. DOI: 10.1182/BLOOD.V106.11.358.358  0.435
2005 Berkofsky-Fessler W, McConnell MJ, Huang K, Bailey ML, Barber DL, Levine RL, Neuberg DS, Gilliland DG, Licht JD. The Transcriptional Profile of PV Displays Limited Similarity to EPO Stimulated Progenitor Cells: Evidence That JAK2 V617F Confers a Novel Program to Malignant Hematopoietic Stem Cells. Blood. 106: 120-120. DOI: 10.1182/blood.v106.11.120.120  0.333
2004 Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature Medicine. 10: 1329-35. PMID 15531890 DOI: 10.1038/Nm1134  0.5
2004 Takahashi S, Harigae H, Kaku M, Sasaki T, Licht JD. Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5. Biochemical and Biophysical Research Communications. 316: 85-92. PMID 15003515 DOI: 10.1016/j.bbrc.2004.02.018  0.314
2004 Takahashi S, McConnell MJ, Harigae H, Kaku M, Sasaki T, Melnick AM, Licht JD. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood. 103: 4650-8. PMID 14982881 DOI: 10.1182/blood-2003-08-2759  0.539
2004 Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, Bardwell VJ, Licht JD, Melnick A. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood. 103: 1454-63. PMID 14551142 DOI: 10.1182/Blood-2003-06-2081  0.578
2004 Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Silva GFD, Prive GG, Licht JD, Melnick A. Specific Peptide Disruption of the Bcl-6 Repression Complex Reveals Its Transcriptional Mechanism of Action in Normal and Malignant B-Cells and Is a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma. Blood. 104: 5-5. DOI: 10.1182/Blood.V104.11.5.5  0.566
2004 McConnell M, Langley E, Martinez-Martinez Y, Kouzarides T, Licht JD. Both the Activity and Stability of the Transcriptional Repressor PLZF Are Modified by the Class III Histone Deacetylase SIRT1. Blood. 104: 360-360. DOI: 10.1182/BLOOD.V104.11.360.360  0.391
2004 Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S, Pierce S, Cole PA, Licht JD, Zelent A. Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein. Blood. 104: 359-359. DOI: 10.1182/BLOOD.V104.11.359.359  0.412
2004 Takahashi S, Harigae H, Inomata M, Ishii KK, Licht JD, Sasaki T, Kaku M. Over-Expression of Flt3 Induces the Expression of NFkB Target Genes, cIAP-1 and IL-6. Blood. 104: 2051-2051. DOI: 10.1182/blood.v104.11.2051.2051  0.314
2003 Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, Mayer S, Takahashi S, Licht JD, Privé GG. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Molecular Cell. 12: 1551-64. PMID 14690607 DOI: 10.1016/S1097-2765(03)00454-4  0.532
2003 McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, Licht JD. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Molecular and Cellular Biology. 23: 9375-88. PMID 14645547 DOI: 10.1128/Mcb.23.24.9375-9388.2003  0.324
2003 Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Practice & Research. Clinical Haematology. 16: 387-408. PMID 12935958 DOI: 10.1016/S1521-6926(03)00062-8  0.526
2003 Gross I, Morrison DJ, Hyink DP, Georgas K, English MA, Mericskay M, Hosono S, Sassoon D, Wilson PD, Little M, Licht JD. The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development. The Journal of Biological Chemistry. 278: 41420-30. PMID 12882970 DOI: 10.1074/jbc.M306425200  0.307
2002 Labbaye C, Quaranta MT, Pagliuca A, Militi S, Licht JD, Testa U, Peschle C. PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene. 21: 6669-79. PMID 12242665 DOI: 10.1038/sj.onc.1205884  0.358
2002 Takahashi S, Licht J. The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein Leukemia. 16: 1755-1762. PMID 12200691 DOI: 10.1038/Sj.Leu.2402682  0.412
2002 McLoughlin P, Ehler E, Carlile G, Licht JD, Schäfer BW. The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein. The Journal of Biological Chemistry. 277: 37045-53. PMID 12145280 DOI: 10.1074/jbc.M203336200  0.33
2002 Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Current Opinion in Hematology. 9: 322-32. PMID 12042707 DOI: 10.1097/00062752-200207000-00010  0.561
2002 Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG, Licht JD. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Molecular and Cellular Biology. 22: 1804-18. PMID 11865059 DOI: 10.1128/Mcb.22.6.1804-1818.2002  0.52
2001 Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 20: 7186-7203. PMID 11704847 DOI: 10.1038/Sj.Onc.1204766  0.515
2000 Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood. 96: 3939-47. PMID 11090081 DOI: 10.1182/Blood.V96.12.3939.H8003939_3939_3947  0.572
2000 Houvras Y, Benezra M, Zhang H, Manfredi JJ, Weber BL, Licht JD. BRCA1 physically and functionally interacts with ATF1. The Journal of Biological Chemistry. 275: 36230-7. PMID 10945975 DOI: 10.1074/Jbc.M002539200  0.323
2000 Melnick A, Ahmad KF, Arai S, Polinger A, Ball H, Borden KL, Carlile GW, Prive GG, Licht JD. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Molecular and Cellular Biology. 20: 6550-67. PMID 10938130 DOI: 10.1128/Mcb.20.17.6550-6567.2000  0.485
2000 Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, Lutterbach B, Hiebert SW, Licht JD. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein Molecular and Cellular Biology. 20: 2075-2086. PMID 10688654 DOI: 10.1128/Mcb.20.6.2075-2086.2000  0.547
2000 Melnick A, Westendorf J, Polinger A, Carlile G, Arai S, Ball H, Lutterbach B, Hiebert S, Licht J. Interaction between plzf and eto-a possible link in the molecular mechanisms of M2 and M3 leukemia Experimental Hematology. 28: 129-130. DOI: 10.1016/S0301-472X(00)00500-2  0.557
1999 Melnick A, Fruchtman S, Zelent A, Liu M, Huang Q, Boczkowska B, Calasanz MJ, Fernandez A, Licht JD, Najfeld V. Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21 Leukemia. 13: 1534-1538. PMID 10516754 DOI: 10.1038/Sj.Leu.2401513  0.501
1999 Zhang T, Xiong H, Kan LX, Zhang CK, Jiao XF, Fu G, Zhang QH, Lu L, Tong JH, Gu BW, Yu M, Liu JX, Licht J, Waxman S, Zelent A, et al. Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene. Proceedings of the National Academy of Sciences of the United States of America. 96: 11422-7. PMID 10500192 DOI: 10.1073/Pnas.96.20.11422  0.397
1999 Ball HJ, Melnick A, Shaknovich R, Kohanski RA, Licht JD. The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase Nucleic Acids Research. 27: 4106-4113. PMID 10497277 DOI: 10.1093/Nar/27.20.4106  0.496
1999 English MA, Licht JD. Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control Journal of Biological Chemistry. 274: 13258-13263. PMID 10224085 DOI: 10.1074/jbc.274.19.13258  0.357
1999 Koken MHM, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, De Thé H. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)q23;q21) APL patient Oncogene. 18: 1113-1118. PMID 10023688 DOI: 10.1038/Sj.Onc.1202414  0.326
1999 Hummel JL, Wells RA, Dubé ID, Licht JD, Kamel-Reid S. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene. 18: 633-41. PMID 9989813 DOI: 10.1038/Sj.Onc.1202357  0.339
1999 Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht JD. A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF. Blood. 94: 3737-3747. DOI: 10.1182/Blood.V94.11.3737.423K39_3737_3747  0.534
1999 Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht JD. A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF Blood. 94: 3737-3747. DOI: 10.1182/blood.v94.11.3737  0.534
1999 Melnick A, Licht JD. Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia Blood. 93: 3167-3215. DOI: 10.1182/Blood.V93.10.3167.410K44_3167_3215  0.402
1998 Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent AZ, Licht JD. The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis Molecular and Cellular Biology. 18: 5533-5545. PMID 9710637 DOI: 10.1128/Mcb.18.9.5533  0.513
1997 Koken MHM, Reid A, Quignon F, Chelbi-Alix MK, Davies JM, Kabarowski JHS, Zhu J, Dong S, Chen SJ, Chen Z, Tan CC, Licht J, Waxman S, De Thé H, Zelent A. Leukemia-associated retinoic acid receptor α fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies Proceedings of the National Academy of Sciences of the United States of America. 94: 10255-10260. PMID 9294197 DOI: 10.1073/Pnas.94.19.10255  0.383
1997 Li JY, English MA, Ball HJ, Yeyati PL, Waxman S, Licht JD. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein Journal of Biological Chemistry. 272: 22447-22455. PMID 9278395 DOI: 10.1074/jbc.272.36.22447  0.38
1997 Holmes G, Boterashvili S, English M, Wainwright B, Licht J, Little M. Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins. Biochemical and Biophysical Research Communications. 233: 723-728. PMID 9168922 DOI: 10.1006/Bbrc.1997.6545  0.373
1996 Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Molecular and Cellular Biology. 16: 6945-56. PMID 8943350 DOI: 10.1128/Mcb.16.12.6945  0.31
1996 Dong S, Zhu J, Reid A, Strutt P, Guidez F, Zhong HJ, Wang ZY, Licht J, Waxman S, Chomienne C, Chen Z, Zelent A, Chen SJ. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Proceedings of the National Academy of Sciences of the United States of America. 93: 3624-9. PMID 8622986 DOI: 10.1073/Pnas.93.8.3624  0.395
1995 Reid A, Gould A, Brand N, Cook M, Strutt P, Li J, Licht J, Waxman S, Krumlauf R, Zelent A. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors Blood. 86: 4544-4552. PMID 8541544 DOI: 10.1182/Blood.V86.12.4544.Bloodjournal86124544  0.453
1995 Cook M, Gould A, Brand N, Davies J, Strutt P, Shaknovich R, Licht J, Waxman S, Chen Z, Gluecksohn-Waelsch S, Krumlauf R, Zelent A. Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain Proceedings of the National Academy of Sciences of the United States of America. 92: 2249-2253. PMID 7892256 DOI: 10.1073/Pnas.92.6.2249  0.377
1995 Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, Licht JD. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins Journal of Biological Chemistry. 270: 10878-10884. PMID 7738027 DOI: 10.1074/Jbc.270.18.10878  0.318
1994 Scott A, Kopecky K, Appelbaum F, Theil K, Grever, Chen I, Whittaker M, Griffith B, Licht J. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood. 84: 244-255. DOI: 10.1182/Blood.V84.1.244.Bloodjournal841244  0.304
1993 Licht JD, Ro M, English MA, Grossel M, Hansen U. Selective repression of transcriptional activators at a distance by the Drosophila Krüppel protein Proceedings of the National Academy of Sciences of the United States of America. 90: 11361-11365. PMID 8248254 DOI: 10.1073/Pnas.90.23.11361  0.314
1990 Licht JD, Grossel MJ, Figge J, Hansen UM. Drosophila Krüppel protein is a transcriptional represser Nature. 346: 76-79. PMID 2114551 DOI: 10.1038/346076A0  0.34
Show low-probability matches.